The real-world pain evidence your medical policy team has been asking for.
Coverage decisions for interventional pain procedures — spinal cord stimulation, RF ablation, biologics, neuromodulation — are made with RCT data that doesn't reflect your member population, and claims data that has no functional outcome attached to it. Celéri gives payers structured, longitudinal, PRO-linked real-world evidence from the point of care — so coverage policy, prior authorization criteria, and value-based contracts can be built on what actually happens to patients.
Claims data tells you what was done. It doesn't tell you if it worked.
Payers managing interventional pain spend have access to procedure codes, diagnosis codes, and downstream utilization — but no structured outcome attached to any of it. Did the SCS implant reduce pain and restore function? Did the patient reduce opioid use? Did the RF ablation hold at 12 months? Claims can't answer these questions. Celéri's PainRWD™ Science Cloud can. It is the only de-identified longitudinal database in interventional pain that links procedures to validated patient-reported functional outcomes at 3, 6, and 12 months post-procedure — collected prospectively at the point of care.
Evidence that closes the gap between what was billed and what was gained.
Celéri's data and research infrastructure addresses the specific evidence gaps that drive poor coverage policy, inconsistent prior authorization, and misaligned provider incentives in interventional pain.
Coverage Determination Evidence
When your medical policy team is reviewing coverage for SCS, RF ablation, peripheral nerve stimulation, or emerging neuromodulation therapies — Celéri provides longitudinal, PRO-linked outcomes data from real-world practice populations. Not trial patients. Not claims proxies. Actual functional outcomes from the procedures your members are receiving.
PA Criteria Development & Refinement
Which patient characteristics predict durable outcomes after SCS? Which patients are unlikely to respond? Celéri's structured data — linking baseline diagnoses, severity scores, and prior treatment history to 12-month functional outcomes — can inform PA criteria that approve the right patients faster and reduce inappropriate implants without adding administrative burden.
Opioid Utilization Context
Celéri captures opioid-related PROs alongside procedure outcomes — including PHQ-9, Opioid Risk Tool, and pain severity trajectories. For payers managing interventional procedure spend alongside opioid formulary decisions, Celéri's data provides the linkage that claims alone cannot: what happens to opioid utilization after a successful neuromodulation implant.
Provider Performance & Outcomes-Based Contracting
As payers move toward value-based arrangements with pain practices, outcomes measurement becomes the foundation of the contract. Celéri's point-of-care infrastructure can serve as the measurement layer for outcomes-based agreements — giving both the payer and the practice a shared, validated, longitudinal view of patient outcomes.
Total Cost of Care Modeling
Functional improvement data linked to downstream utilization context — including SDOH enrichment at the ZIP level through Celéri's Socially Determined partnership — supports total cost of care analyses that go beyond episode-level procedure costs. Understand what durable pain relief actually does to downstream ED visits, medication spend, and disability-related costs.
Commissioned Research & Custom Data Analyses
Payers can commission targeted analyses from the PainRWD™ Science Cloud — specific procedure cohorts, geographic subgroups, diagnosis-matched populations, or outcome trajectories for a defined therapy type. Delivered as a structured data package or a published analysis through the Celéri Research Group.
PainRWD™
Science Cloud
The PainRWD™ Science Cloud is Celéri's de-identified longitudinal patient database — built from structured PRO and procedure data collected prospectively across the Celéri practice network at the point of care.
It is not a claims database. It is not survey-based. It is not assembled from EHR notes through NLP. It is structured, validated, patient-reported functional outcomes data linked to specific procedures — collected at clinical milestones before and after treatment, by the treating physician's own practice.
For payers, that distinction matters. This is the evidence your medical directors and HEOR teams have been asking device sponsors to produce for years. Celéri has built it independently — without a manufacturer's fingerprints on it.
The evidence gaps Celéri closes — by role.
Different teams within a payer organization have different evidence needs. Celéri's data and research capabilities address each of them.
Coverage policy decisions grounded in real-world functional outcomes.
Medical policy reviews for interventional procedures rely on clinical literature that is often years old, controlled-trial-based, and poorly representative of your member population. Celéri provides current, real-world PRO data — by procedure type, diagnosis, and patient profile — that your medical directors can actually use to set and defend coverage criteria.
- Coverage determination evidence — procedure-level outcome data
- Comparative effectiveness across therapy types
- Patient subgroup analysis by diagnosis and baseline severity
- Independent data — no manufacturer bias
Total cost of care modeling with functional outcomes attached.
HEOR teams need more than claims data to model the full value of an interventional procedure. Celéri's structured PRO data — linked to SDOH context and enriched with downstream utilization proxies — gives your health economists the functional outcome layer that turns a cost analysis into a value analysis.
- Functional outcome trajectories at 3, 6, and 12 months
- SDOH enrichment for equity and social risk modeling
- Opioid utilization context alongside procedure outcomes
- Custom cohort analysis — commissioned through Celéri Research Group
PA criteria that approve the right patients — not just the right codes.
Prior authorization for SCS and other high-cost interventional procedures is a high-stakes decision made with inadequate evidence. Celéri's data on which patient characteristics predict durable outcomes — and which don't — gives utilization management teams the real-world signal to calibrate PA criteria more precisely than clinical guidelines alone allow.
- Responder profile analysis — who benefits most, and from which therapy
- Baseline severity and prior treatment history linked to outcomes
- Identify appropriate vs. inappropriate implant patterns
- Reduce administrative friction for high-probability responders
Outcomes-based provider contracts built on shared, validated data.
Moving toward outcomes-based arrangements with pain practices requires a measurement infrastructure that both the payer and the provider trust. Celéri's point-of-care PRO infrastructure — already deployed at interventional pain practices — can serve as the neutral, validated measurement layer for value-based contracts, giving both parties a shared view of what happened to the patient.
- Practice-level outcomes data — procedure-specific and longitudinal
- Shared measurement infrastructure for VBC contract design
- Provider performance benchmarking across the Celéri network
- Identify high-performing practices for preferred network designation
How payers engage with Celéri's data.
Each payer engagement is scoped to the specific evidence need. Most organizations find that multiple use cases apply once the data is in hand.
| Payer Function | Evidence Need | Celéri Asset | Delivery Format |
|---|---|---|---|
| Medical Policy | Real-world outcomes evidence for SCS or neuromodulation coverage review | PainRWD™ Science Cloud Licensed Dataset | Structured data package or commissioned analysis report |
| Medical Policy | Comparative effectiveness across competing therapy types | PainRWD™ Science Cloud Custom Analysis | Research report with biostatistical support |
| Prior Authorization | Identify patient profile predictors of durable SCS outcomes | PainRWD™ Science Cloud Responder Analysis | Analytic report; PA criteria recommendations optional |
| HEOR | Total cost of care modeling with functional outcomes attached | PainRWD™ + SDOH Enrichment HEOR | Custom model; publishable analysis available |
| Pharmacy / UM | Opioid utilization patterns before and after neuromodulation | PainRWD™ Science Cloud Drug Utilization | Cohort analysis — diagnosis-matched and procedure-matched |
| Network / VBC | Outcomes measurement layer for value-based pain practice contracts | PainIntel™ Deployment Measurement Layer | Point-of-care PRO infrastructure; practice-level reporting |
| Network / VBC | Provider performance benchmarking across interventional pain practices | PainRWD™ Science Cloud Network Analysis | Practice-level outcomes benchmarking report |
Independent evidence. No manufacturer fingerprints.
Payers routinely receive outcomes data from device manufacturers in support of coverage requests — data generated by the manufacturer's own sponsored registry, analyzed by the manufacturer's own team, and delivered with the manufacturer's commercial objective in mind. Celéri is not a device company. We have no therapy to sell and no reimbursement outcome to influence. The PainRWD™ Science Cloud is built by an independent evidence infrastructure company whose only interest is the integrity of the data. That independence is what makes it useful to payers.
What payer teams ask us most.
-
Manufacturer-sponsored registry data is generated under a protocol designed by the manufacturer, analyzed by teams with a commercial interest in the outcome, and delivered in support of a specific coverage or reimbursement request. PainRWD™ is built by Celéri — an independent evidence infrastructure company with no therapy to sell and no reimbursement outcome to influence. The data is collected prospectively from real-world clinical practice, across multiple procedure types and therapy categories, and governed independently. That independence is what makes it a credible reference for medical policy purposes.
-
Yes. All data in the PainRWD™ Science Cloud is de-identified per HIPAA Safe Harbor standards. Celéri handles PHI stripping, normalization, and Safe Harbor de-identification as the data steward. Practices contribute data under Celéri's data use framework — patients are never in a direct data relationship with payers or any downstream data user. Individual-level patient matching for specific analyses may require IRB coordination or updated consent, depending on the study design.
-
Yes. Payers can commission targeted analyses from the PainRWD™ Science Cloud — specific procedure cohorts (e.g., SCS for failed back surgery syndrome vs. CRPS), geographic subgroups, diagnosis-matched populations, or outcome trajectories for a defined therapy type. Custom analyses are delivered through the Celéri Research Group, with biostatistical support from Hart Clinical Consultants. Contact the Celéri evidence team to scope a specific analysis request.
-
Yes. ZIP-level social determinant of health data is available immediately through Celéri's partnership with Socially Determined — no patient data transfer required for ZIP-level enrichment. Individual-level SDOH matching requires IRB coordination or updated consent. For payers interested in health equity analysis, total cost of care modeling, or social risk stratification alongside interventional pain outcomes, the SDOH enrichment layer is available as part of a custom data engagement.
-
Yes, and this is an area Celéri is actively developing. PainIntel — Celéri's point-of-care outcomes platform — is already deployed at interventional pain practices and collecting longitudinal PRO data at every clinical milestone. For payers designing outcomes-based arrangements with pain practices, PainIntel can serve as the neutral measurement infrastructure that both the payer and the practice trust. Contact us to discuss how a value-based contracting pilot could be structured.
-
The PainRWD™ Science Cloud covers a broad range of interventional pain and neuromodulation procedures — including spinal cord stimulation (all waveforms), RF ablation, peripheral nerve stimulation, intrathecal drug delivery systems, vertebroplasty/kyphoplasty, epidural steroid injections, and adjacent interventional procedures. Biologics and regenerative medicine procedures are also represented. Coverage continues to expand as the Celéri practice network grows. Contact us for current procedure-level coverage details relevant to your review.
Tell us what coverage question you're trying to answer.
Whether your medical policy team is reviewing SCS coverage criteria, your HEOR team needs a total cost of care analysis, or your network team is exploring outcomes-based contracting — Celéri's evidence team can scope the right data engagement.
